HSV2 gB Specific Neutra™ Antibody Products

Are you grappling with prolonged timelines in antiviral drug development or challenges in generating neutralizing antibodies that block viral entry? Creative Biolabs' HSV2 gB specific Neutra™ antibody products leverage advanced single-B-cell cloning platforms and epitope-guided engineering to deliver highly specific, affinity-matured antibodies, enabling rapid validation of HSV2 therapeutics and diagnostics.

Introduction to HSV2 gB

Human herpesvirus 2 glycoprotein B (HSV2 gB) is a transmembrane protein essential for viral entry into host cells. As a conserved component of the herpesvirus envelope, it mediates membrane fusion and cell-to-cell spread during infection. HSV2 gB is a critical immunogen, eliciting neutralizing antibodies that disrupt viral infectivity, making it a prime target for therapeutic and prophylactic interventions.

• Structural Insights

HSV2 gB adopts a trimeric configuration stabilized by disulfide bonds, with distinct domains enabling receptor binding and fusion activation. Its N-terminal region engages host cell surface heparan sulfate proteoglycans (HSPGs), while the C-terminal fusion domain facilitates pH-dependent membrane penetration. Cryo-EM studies reveal conformational flexibility in the post-fusion state, highlighting targets for neutralizing antibodies to lock gB in pre-fusion conformations.

Fig.1 Crystal structure of gB.¹

• Related Signaling Pathways

HSV2 gB interaction with host receptors triggers calcium signaling and NF-κB activation, promoting viral entry and immune evasion. Concurrently, it downregulates interferon (IFN) pathways by suppressing STAT1 phosphorylation, enabling unchecked viral replication. Neutralizing antibodies against gB counteract these mechanisms by blocking receptor engagement and restoring innate immune responses.

• Associated Pathologies

HSV2 is the primary etiological agent of genital herpes, a chronic infection affecting over 500 million individuals globally. Persistent viral shedding drives recurrent lesions, neonatal transmission risks, and increased susceptibility to HIV coinfection. Current antivirals only suppress symptoms, underscoring the unmet need for curative therapies targeting viral entry mechanisms.

Applications of HSV2 gB Neutralizing Antibodies

• Prophylactic Protection

Neutralizing antibodies administered pre-exposure prevent genital herpes transmission by forming a protective barrier at mucosal surfaces. Passive immunization strategies using IgG1-isotype antibodies have demonstrated >80% efficacy in blocking viral shedding in preclinical models, offering potential for high-risk populations such as serodiscordant couples.

• Therapeutic Intervention

In established infections, neutralizing antibodies reduce lesion severity and recurrence by targeting free virions and infected cells. Combination therapy with drugs synergistically lowers viral loads by 99% in latency models, suggesting utility in suppressing reactivation and mitigating drug resistance.

• Diagnostic Development

Antibodies against HSV2 gB enable ultrasensitive detection of viral antigens in clinical samples. ELISA-based assays using these reagents achieve <1 pg/mL sensitivity, supporting early diagnosis and monitoring of treatment efficacy in asymptomatic carriers.

• Vaccine Efficacy Evaluation

HSV2 gB antibodies serve as correlates of protection in vaccine trials. Quantifying neutralizing titers post-vaccination predicts immune efficacy, as demonstrated in phase I studies where antibody-mediated viral neutralization correlated with reduced infection rates.

Our Anti-HSV2 gB Antibody Products

Creative Biolabs' HSV2 gB-specific neutralizing antibodies are engineered to disrupt key functional domains:

- Receptor Binding Inhibition: Antibodies targeting the N-terminal HSPG-binding region prevent viral attachment to host cells.

- Fusion Blockade: High-affinity binders to the C-terminal fusion domain stabilize the pre-fusion trimer, halting membrane penetration.

- Immune Modulation: Fc-engineered variants enhance antibody-dependent cellular cytotoxicity (ADCC), promoting clearance of infected cells.

Validated in pseudovirus neutralization assays and in vivo models, these antibodies exhibit >90% inhibition of viral entry at nanomolar concentrations, positioning them as leading candidates for therapeutic and vaccine development.

Creative Biolabs offers HSV2 gB specific Neutra™ antibody products combining cutting-edge specificity with robust preclinical validation to address critical gaps in herpesvirus research and therapy development.

Contact our team today to explore tailored solutions for your antiviral programs.

REFERENCE

1. Madavaraju, Krishnaraju, et al. "Herpes simplex virus cell entry mechanisms: an update." Frontiers in cellular and infection microbiology 10 (2021): 617578. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fcimb.2020.617578